Role of Single-Pill Combination Therapy in Optimizing Blood Pressure Control in High-Risk Hypertension Patients and Management of Treatment-Related Adverse Events

Journal of Clinical Hypertension

Volumn 14, Issue 10, 2012, Pages 718-726

  Abdellatif, Abdul Ali ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Kidney Hypertension Transplant Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; GLUCONATE CALCIUM; HYDROCHLOROTHIAZIDE; INSULIN; OLMESARTAN; RAMIPRIL; SALBUTAMOL; SPIRONOLACTONE; TELMISARTAN; VALSARTAN;

BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; COMORBIDITY; DIABETES MELLITUS; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; HEART FAILURE; HIGH RISK PATIENT; HUMAN; HYPERKALEMIA; HYPERTENSION; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM RESTRICTION;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIABETES MELLITUS; HEART FAILURE; HUMANS; HYPERKALEMIA; HYPERTENSION; RENAL INSUFFICIENCY, CHRONIC; RENIN-ANGIOTENSIN SYSTEM; RISK ASSESSMENT;

EID: 84867101113     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2012.00696.x     Document Type: Review

References (53)

1. Centers for Disease Control and Prevention. Vital signs: prevalence, treatment, and control of hypertension-United States, 1999-2002 and 2005-2008. MMWR Morb Mortal Wkly Rep. 2011;60:103-108.
2. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA. 2010;303:2043-2050.
3. Wong ND, Lopez VA, L'Italien G, et al. Inadequate control of hypertension in US adults with cardiovascular disease comorbidities in 2003-2004. Arch Intern Med. 2007;167:2431-2436.
4. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28:1462-1536.
5. Cordero A, Bertomeu-Martínez V, Mazón P, et al. [Factors associated with uncontrolled hypertension in patients with and without cardiovascular disease]. Rev Esp Cardiol. 2011;64:587-593.
6. Makris A, Seferou M, Papadopoulos DP. Resistant hypertension workup and approach to treatment. Int J Hypertens. 2010;2011:598694.
7. Jackson JH, Frech F, Ronen R, et al. Assessment of drug therapy management and the prevalence of heart failure in a managed care population with hypertension. J Manag Care Pharm. 2004;10:513-520.
8. Zarini GG, Exebio JC, Gundupalli D, et al. Hypertension, poor glycemic control, and microalbuminuria in Cuban Americans with type 2 diabetes. Int J Nephrol Renovasc Dis. 2011;4:35-40.
9. Roumie CL, Ofner S, Ross JS, et al. Prevalence of inadequate blood pressure control among veterans after acute ischemic stroke hospitalization: a retrospective cohort. Circ Cardiovasc Qual Outcomes. 2011;4:399-407.
10. Judd SE, McClure LA, Howard VJ, et al. Heavy drinking is associated with poor blood pressure control in the REasons for Geographic and Racial Differences in Stroke (REGARDS) study. Int J Environ Res Public Health. 2011;8:1601-1612.
11. Flack JM, Sica DA, Bakris G, et al. Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement. Hypertension. 2010;56:780-800.
12. National Kidney Foundation. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43(5 suppl 1):S1-S290.
13. Bangalore S, Kumar S, Lobach I, Messerli FH. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and Bayesian random-effects meta-analyses of randomized trials. Circulation. 2011;123:2799-2810.
14. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206-1252.
15. Weir MR. Providing end-organ protection with renin-angiotensin system inhibition: the evidence so far. J Clin Hypertens (Greenwich). 2006;8:99-105.
16. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290:2805-2816.
17. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417-2428.
18. Dicpinigaitis PV. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest. 2006;129(1 suppl):169S-173S.
19. Byrd JB, Adam A, Brown NJ. Angiotensin-converting enzyme inhibitor-associated angioedema. Immunol Allergy Clin North Am. 2006;26:725-737.
20. Yang W, Chang J, Kahler KH, et al. Evaluation of compliance and health care utilization in patients treated with single pill vs. free combination antihypertensives. Curr Med Res Opin. 2010;26:2065-2076.
21. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med. 2004;351:585-592.
22. Makani H, Bangalore S, Romero J, et al. Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate - a meta-analysis of randomized trials. J Hypertens. 2011;29:1270-1280.
23. Palmer BF. A physiologic-based approach to the evaluation of a patient with hyperkalemia. Am J Kidney Dis. 2010;56:387-393.
24. Salem MM. Pathophysiology of hypertension in renal failure. Semin Nephrol. 2002;22:17-26.
25. Chow KM, Szeto CC, Law MC, et al. Impact of early nephrology referral on mortality and hospitalization in peritoneal dialysis patients. Perit Dial Int. 2008;28:371-376.
26. Nakamura S, Nakata H, Yoshihara F, et al. Effect of early nephrology referral on the initiation of hemodialysis and survival in patients with chronic kidney disease and cardiovascular diseases. Circ J. 2007;71:511-516.
27. Parati G, Bilo G, Ochoa JE. Benefits of tight blood pressure control in diabetic patients with hypertension: importance of early and sustained implementation of effective treatment strategies. Diabetes Care. 2011;34(suppl 2):S297-S303.
28. Wang J, Geiss LS, Cheng YJ, et al. Long-term and recent progress in blood pressure levels among U.S. adults with diagnosed diabetes, 1988-2008. Diabetes Care. 2011;34:1579-1581.
29. Persson F, Lewis JB, Lewis EJ, et al. Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy. Diabetes Care. 2010;33:2304-2309.
30. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547-553.
31. D'Elia JA, Bayliss G, Roshan B, et al. Diabetic microvascular complications: possible targets for improved macrovascular outcomes. Int J Nephrol Renovasc Dis. 2011;4:1-15.
32. Manickavasagam S, Merla R, Koerner MM, et al. Management of hypertension in chronic heart failure. Expert Rev Cardiovasc Ther. 2009;7:423-433.
33. Unger T, Li J. The role of the renin-angiotensin-aldosterone system in heart failure. J Renin Angiotensin Aldosterone Syst. 2004;5(suppl 1):S7-S10.
34. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717.
35. Lehnhardt A, Kemper MJ. Pathogenesis, diagnosis and management of hyperkalemia. Pediatr Nephrol. 2011;26:377-384.
36. McIntyre WF, Femenía F, Arce M, et al. Importance of early electrocardiographic recognition and timely management of hyperkalemia in geriatric patients. Exp Clin Cardiol. 2011;16:47-50.
37. Munar MY, Singh H. Drug dosing adjustments in patients with chronic kidney disease. Am Fam Physician. 2007;75:1487-1496.
38. Phillips CO, Kashani A, Ko DK, et al. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Arch Intern Med. 2007;167:1930-1936.
39. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med. 2004;351:543-551.
40. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-1559.
41. European Medicines Agency. European Medicines Agency starts review of aliskiren-containing medicines following termination of ALTITUDE study. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/12/news_detail_001417.jsp&mid=WC0b01ac058004d5c1. Accessed May 9, 2012.
42. Mangrum AJ, Bakris GL. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: safety issues. Semin Nephrol. 2004;24:168-175.
43. Hollander-Rodriguez JC, Calvert JF Jr. Hyperkalemia. Am Fam Physician. 2006;73:283-290.
44. Karet FE. Mechanisms in hyperkalemic renal tubular acidosis. J Am Soc Nephrol. 2009;20:251-254.
45. Pfizer Labs. Norvasc® (Amlodipine Besylate) Tablets [Prescribing Information]. New York, NY: Pfizer Labs; 2011.
46. Epstein BJ, Roberts ME. Managing peripheral edema in patients with arterial hypertension. Am J Ther. 2009;16:543-553.
47. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119:e391-e479.
48. Makani H, Bangalore S, Romero J, et al. Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema. Am J Med. 2011;124:128-135.
49. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55:399-407.
50. Zeng F, Patel BV, Andrews L, et al. Adherence and persistence of single-pill ARB/CCB combination therapy compared to multiple-pill ARB/CCB regimens. Curr Med Res Opin. 2010;26:2877-2887.
51. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120:713-719.
52. Sherrill B, Halpern M, Khan S, et al. Single-pill vs free-equivalent combination therapies for hypertension: a meta-analysis of health care costs and adherence. J Clin Hypertens (Greenwich). 2011;13:898-909.
53. Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs. 2002;62:443-462.